This is a single ascending dose, first-in-human study to determine the safety, tolerability, and pharmacokinetics (PK) of ARCT-032. After screening, participants will be randomized 3:1 to receive a single dose of nebulized ARCT-032 or placebo by inhalation. There are 4 planned sequential dose cohorts. After dosing, participants will have follow-up assessments over a 4-week time period.
Determine the safety, tolerability and pharmacokinetics of single doses of ARCT-032 in healthy adult subjects.